Derek Brown
Vice President, Global Commercial Development Lead at Rallybio | New York City Metropolitan Area, United States
Derek Brown’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Vice President, Global Commercial Development Lead at Rallybio in January 2022 - Present
Vice President, Marketing & Commercial Operations at Chiasma / acquired by Amryt Pharma at Chiasma in September 2019 - December 2021
Principal/Owner of Independent Biopharmaceutical Consulting Business at DSB Consulting in January 2018 - January 2019
Executive Director, Global Commercial Lead Ultomiris® and Global Soliris® PNH Marketing Lead at Alexion Pharmaceuticals, Inc. in January 2015 - January 2018
Executive Director, Marketing at Boehringer Ingelheim in January 2014 - January 2015
Executive Director and Global Team Leader, Marketing Pipeline Products, Ingelheim, Germany at Boehringer Ingelheim in January 2011 - January 2014
Associate Director, Managed Markets Marketing at Boehringer Ingelheim in January 2009 - January 2011
Associate Director CNS Marketing at Boehringer Ingelheim in January 2008 - January 2009
Associate Director, Pipeline Marketing at Boehringer Ingelheim in January 2007 - January 2008
Product Manager, Respiratory at Boehringer Ingelheim in January 2006 - January 2007
Associate Product Manager, MOBIC® at Boehringer Ingelheim in January 2005 - January 2006
Senior Marketing Analyst at Boehringer Ingelheim in January 2003 - January 2005
Business Consultant at Woomera Therapeutics Inc in January 2002 - January 2003
Summer Finance Associate at Pfizer in June 2002 - August 2002
Solutions Manager for Consulting Engagements at Intrasphere Technologies in January 2000 - January 2001
Consultant at Accenture in January 1997 - January 2000
Dartmouth College - The Tuck School of Business at Dartmouth, Master of Business Administration (MBA)
Middlebury College, B.A. Economics; Cellular Structure and Function
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Rallybio’s pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut.
Discover more about Rallybio
Corporate Development & Financial Planning at Rallybio
Executive Director, Corporate Development & Financial Planning at Rallybio
(November 2023 – Present)
Corporate Strategy & New Product Planning at Rallybio
Associate Director, Corporate Strategy & New Product Planning at Rallybio
(April 2022 – Present)
Senior Vice President, External Research & Project Management
Steering Committee Member at Executive Women in Bio
(August 2022 – Present)
Co-Founder at Rallybio
Co-Founder at Rallybio
(2018 – Present)
Board Member | Audit Committee Chair | Public Company CFO | Biotech/Pharma Executive
Board Member at Rallybio
(Sep 2020 – Present)
Clinical Operations Lead
Clinical Operations at Rallybio
(May 2021 – Present)
What is Derek Brown email address?
Email Derek Brown at [email protected], [email protected], [email protected] and [email protected]. This email is the most updated Derek Brown's email found in 2026.
How to contact Derek Brown?
To contact Derek Brown send an email to [email protected], [email protected], [email protected] or [email protected].
What company does Derek Brown work for?
Derek Brown works for Rallybio.
What is Derek Brown's role at Rallybio?
Derek Brown is Vice President, Global Commercial Development Lead
What industry does Derek Brown work in?
Derek Brown works in the Pharmaceuticals industry.
